Cargando…

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

BACKGROUND: Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neuroblastoma....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Zhi-Xia, Xing, Tian-Yu, Gao, Chao, Liu, Shu-Guang, Zhao, Wen, Zhao, Qian, Wang, Xi-Si, Jin, Mei, Ma, Xiao-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829843/ https://www.ncbi.nlm.nih.gov/pubmed/31685009 http://dx.doi.org/10.1186/s40880-019-0409-1

Ejemplares similares

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion
por: Villamón, Eva, et al.
Publicado: (2013)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma
por: Yue, Zhi-Xia, et al.
Publicado: (2017)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma
por: Yue, Zhi‐Xia, et al.
Publicado: (2022)

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy
por: Lu, Xian-Ying, et al.
Publicado: (2022)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)

Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells
por: Jurcevic, Sanja, et al.
Publicado: (2022)

Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis
por: Luttikhuis, M E M Oude, et al.
Publicado: (2001)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Detailed deletion mapping at chromosome 11q23 in colorectal carcinoma
por: Lee, A S-G, et al.
Publicado: (2000)

Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Clinical value of (18)F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma
por: Ren, Jiazhong, et al.
Publicado: (2023)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon’s perspective
por: Chui, Chanhon
Publicado: (2020)

Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival
por: Bray, Isabella, et al.
Publicado: (2009)

Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival
por: Keane, Simon, et al.
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma via Pre-therapy 18F-FDG PET/CT Radiomics
por: Qian, Luodan, et al.
Publicado: (2022)

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma
por: Panachan, Jirawan, et al.
Publicado: (2022)

Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss
por: Hoshi, M, et al.
Publicado: (2000)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
por: Seier, Johanna A, et al.
Publicado: (2021)

Chromosome 11q13 deletion syndrome
por: Kim, Yu-Seon, et al.
Publicado: (2016)

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk
por: Chang, Xiao, et al.
Publicado: (2017)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

11q deletion in neuroblastoma: a review of biological and clinical implications
por: Mlakar, Vid, et al.
Publicado: (2017)

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
por: Zhang, Peng, et al.
Publicado: (2017)

Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples
por: Somasundaram, Dinesh Babu, et al.
Publicado: (2019)

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma
por: Chen, Xin, et al.
Publicado: (2021)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma
por: Xia, Yuren, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7m9t2qua7e6otb8ovhrcitraou